Oral potassium arsenite used to be an important antileukemic agent 1 until the 1950s, when it was surpassed by modern chemotherapeutic drugs. The use of arsenic resurged when its high efficacy was shown in acute promyelocytic leukemia (APL). 2, 3 However, to date, only intravenous As 2 O 3 has been used. We have recently redeveloped an oral preparation of As 2 O 3 , 4 which achieved total blood cell and plasma levels of elemental arsenic comparable with those of intravenous As 2 O 3 .
Treated with oral As 2 O 3 were 12 consecutive unselected patients with relapsed APL (Table 1 ). The relapse was confirmed morphologically (Ͼ 30% blasts ϩ abnormal promyelocytes in the marrow) and cytogenetically (presence of t(15;17), with none of the cases showing additional karyotyic aberrations) or molecularly (presence of PML /RARA). The treatment was given with informed consent, and the protocol was approved by the institutional review board of the University of Hong Kong. All patients had a pretreatment Karnofsky score higher than 80%. Routine monitoring included alternate daily blood counts and renal/liver function tests (LFTs), and electrocardiography (ECG) daily in the initial week, then weekly.
There were 8 patients in first relapse (R1) treated with oral As 2 O 3 (10 mg/d) until complete remission (CR; Ͻ 5% of abnormal promyelocytes ϩ blasts in the marrow), followed by consolidation with idarubicin (6 mg/m 2 /d, 5 days in the first month, then 2 days per month for 2 months). 5 Cases 1, 2, 3, 5, and 7 received one day of intravenous As 2 O 3 as part of the initial pharmacokinetic study. 4 All patients achieved CR2 with oral As 2 O 3 , given for a median of 37 days (range, 22-59 days). At a median follow-up of 14 months (range, 6-18 months), 7 patients were in continuous CR2.
In R2, 5 patients (including case 1, who relapsed after CR2) were treated with a combination of oral As 2 O 3 (10 mg/d) and all-trans retinoic acid (ATRA; 45 mg/m 2 /d) until remission, 6 followed by 6 PML /RARA remained positive in all patients after As 2 O 3 -induced CR. However, PML /RARA became negative in 11 cases 3 to 6 months after remission, and remained negative until the latest bone marrow examination. Polymerase chain reaction (PCR) in patient 1 became positive shortly before R2.
Of the patients, 4 (cases 1, 4, 10, and 12) developed leucocytosis (median, 74 ϫ 10 9 /L [range, 62-120 ϫ 10 9 /L]) requiring idarubicin (6 mg/m 2 /d ϫ 5, given when white cell count Ͼ 15 ϫ 10 9 /L) for control. However, symptomatology similar to the ATRA syndrome 7 was not observed. Impairment of LFTs occurred in 5 patients, peaking at a median of 11 days (range, 5-21 days). LFTs DFS indicates disease-free survival; M, male; R1, first relapse; ATRA, all-trans retinoic acid; Dauno, daunorubicin; Ida, idarubicin; CR, complete remission; -, none; IV, intravenous; R2, second relapse; NR, nonremission; F, female; AML; acute myeloid leukemia; NA, no additional Rx; CRF, chronic renal failure; DM, diabetes mellitus; CAPD, continuous ambulatory peritoneal dialysis; Ara-c, cytosine arabinoside; CRHD, chronic rheumatic heart disease; and rep, replacement.
*Pharmacokinetic data of oral As2O3 have previously been reported. 4 † PCR for PML/RARA. ϩ indicates positive; Ϫ, negative, (time from initial diagnosis).
normalized after temporary cessation of treatment, and further oral As 2 O 3 therapy was not compromised. Mild skin rashes (grade I) developed in 5 patients and subsided with symptomatic treatment. Headache developed in 2 patients on oral As 2 O 3 /ATRA, and subsided when the dose of ATRA was split. None of our patients showed ECG abnormalities of the types previously reported. 8 Our preliminary results in this pilot study showed that oral As 2 O 3 was highly active in relapsed APL, with an efficacy comparable with intravenous As 2 O 3 . 9 The side effects, including the frequency and severity of leucocytosis, LFT derangement, and skin rashes, were also comparable with intravenous As 2 O 3 . 2,3 Cardiac arrhythmias were not found, which was similar to a previous study of intravenous As 2 O 3 in Chinese patients, where arrhythmia was seen in only 1 of 58 patients. 2 It is important to note that only 4 patients received oral As 2 O 3 as a single agent for CR induction, with the rest having received ATRA or idarubicin before CR was reached. With this limitation, our results showed that oral As 2 O 3 had a short-term efficacy and safety profile similar to intravenous As 2 O 3 . A recent study also showed that oral tetra-arsenic tetrasulfide was highly efficacious in APL. 10 However, the long-term efficacy and safety of oral As 2 O 3 compared with intravenous As 2 O 3 will require longer follow-up. Finally, although oral or intravenous As 2 O 3 and hematopoietic stem cell transplantation are effective treatment modalities for patients with relapsed APL, their relative merits are undefined, and further randomized trials will be needed to address this issue. 
To the editor:
No clinical evidence for CD4 ؉ cell depletion caused by rituximab
In the recent letter "Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab" 1 Herbert et al inaccurately stated that "the severe CD4 lymphopenia induced by alemtuzumab and other monoclonal therapies such as rituximab for lymphoproliferative diseases is a risk factor for opportunistic infections." 1(p1654) Rituximab (Rituxan; IDEC Pharmaceuticals, San Diego, CA/ Genentech, South San Francisco, CA) is an FDA-approved therapeutic monoclonal antibody directed against CD20, an antigen expressed uniquely on cells of the B-lymphocyte lineage, but not on T lymphocytes. In contrast, CD4 is expressed on T lymphocytes, macrophages, and microglial cells, but not on B lymphocytes. Although parvovirus B19 infection has been reported in a patient treated with rituximab, 2 we are not aware of any data suggesting that administration of rituximab leads to a depletion of CD4 ϩ T cells. In fact, flow cytometry data from 166 patients treated with rituximab in a clinical trial showed no diminution of absolute numbers of CD3 ϩ , CD4 ϩ , CD8 ϩ , or natural killer cells. 
